Axis Therapeutics Announces Research Collaboration with PharmaEssentia for Development of TCR-T Cell Therapy in Taiwan

NEXT STORY
Merus and myTomorrows Announce Expansion of Collaboration for Screening and eNRGy Clinical Trial Awareness for Cancer Patients with Neuregulin 1 Fusion Tumors
PREV STORY
Inventiva receives FDA Breakthrough Therapy designation for lead drug candidate lanifibranor in NASH
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Oral semaglutide provides superior HbA1c and weight reductions versus placebo in people with type 2 diabetes and renal impairment in the PIONEER 5 trial

Bagsværd, Denmark, 20 August 2018 - Novo Nordisk today announced the headline results from ...

author_avatar
NASDAQ Market News

UroGen Pharma to Report First Quarter 2018 Financial Results on Tuesday, May 15, 2018

Conference Call and Webcast Scheduled for 8:30 AM ET RA’ANANA, Israel and NEW YORK, May ...

author_avatar
NASDAQ Market News

Inovio’s SynCon® WT1 Cancer Antigen Breaks Tolerance, Highlights Potential for Universal Cancer Immunotherapy

PLYMOUTH MEETING, Pa., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today ...

author_avatar
NASDAQ Market News